DE69730045D1 - Behandlung der harninkontinenz und zusammenstellung dafür - Google Patents

Behandlung der harninkontinenz und zusammenstellung dafür

Info

Publication number
DE69730045D1
DE69730045D1 DE69730045T DE69730045T DE69730045D1 DE 69730045 D1 DE69730045 D1 DE 69730045D1 DE 69730045 T DE69730045 T DE 69730045T DE 69730045 T DE69730045 T DE 69730045T DE 69730045 D1 DE69730045 D1 DE 69730045D1
Authority
DE
Germany
Prior art keywords
treatment
compilation
therefor
urine incontinence
urinary incontinence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69730045T
Other languages
English (en)
Other versions
DE69730045T2 (de
Inventor
John Mcmichael
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Milkhaus Laboratory Inc
Original Assignee
Milkhaus Laboratory Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Milkhaus Laboratory Inc filed Critical Milkhaus Laboratory Inc
Publication of DE69730045D1 publication Critical patent/DE69730045D1/de
Application granted granted Critical
Publication of DE69730045T2 publication Critical patent/DE69730045T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69730045T 1996-10-17 1997-10-16 Behandlung der harninkontinenz und zusammenstellung dafür Expired - Lifetime DE69730045T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US731702 1996-10-17
US08/731,702 US5877198A (en) 1996-10-17 1996-10-17 Treatment of urinary incontinence
PCT/US1997/018601 WO1998016225A1 (en) 1996-10-17 1997-10-16 Treatment of urinary incontinence and compositions for use therein

Publications (2)

Publication Number Publication Date
DE69730045D1 true DE69730045D1 (de) 2004-09-02
DE69730045T2 DE69730045T2 (de) 2005-07-21

Family

ID=24940633

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69730045T Expired - Lifetime DE69730045T2 (de) 1996-10-17 1997-10-16 Behandlung der harninkontinenz und zusammenstellung dafür

Country Status (9)

Country Link
US (1) US5877198A (de)
EP (1) EP0946174B1 (de)
JP (1) JP2001502336A (de)
AT (1) ATE271867T1 (de)
AU (1) AU729675B2 (de)
CA (1) CA2269031C (de)
DE (1) DE69730045T2 (de)
IL (1) IL129267A (de)
WO (1) WO1998016225A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6156780A (en) * 1996-10-17 2000-12-05 Milkhaus Laboratory, Inc. Treatment of fecal incontinence
WO2014066672A1 (en) * 2012-10-26 2014-05-01 Beech Tree Labs, Inc. Method of treating muscular weakness comprising administering a composition comprising an effective amount of histamine and/or serotonin
WO2019126737A1 (en) 2017-12-21 2019-06-27 Resolys Bio, Inc. Compositions and methods of treatment of ehlers-danlos syndromes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880626A (en) * 1985-01-18 1989-11-14 Mcmichael John Immunotherapeutic methods and compositions for the treatment of diseases of viral origin, including acquired immune deficiency syndrome
US4970071A (en) * 1985-01-18 1990-11-13 Mcmichael John Immunotherapeutic methods and compositions employing antigens characteristic of non human malignant neoplasms
US4692332A (en) * 1985-01-18 1987-09-08 Mcmichael John Immunotherapeutic methods and compositions employing antigens characteristic of malignant neoplasms
US4689222A (en) * 1985-01-18 1987-08-25 Mcmichael John Methods and materials for alleviation of pain symptoms of malignant neoplasia
US4966753A (en) * 1987-08-18 1990-10-30 Molecular Rx, Inc. Immunotherapeutic methods and compositions employing antigens characteristic of malignant neoplasms
AU2485988A (en) * 1987-09-10 1989-04-17 John Mcmichael Method and composition for enhancing animal fertility
JP2980677B2 (ja) * 1990-04-27 1999-11-22 マクマイケル，ジョン 不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物
ATE202940T1 (de) * 1994-05-25 2001-07-15 John Mcmichael Mittel und methoden zur behandlung von plaque- krankheiten
FR2732017B1 (fr) * 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
WO1996032138A1 (en) * 1995-04-13 1996-10-17 Milkhaus Laboratory, Inc. Methods for treating respiratory disease
US5610174A (en) * 1995-06-02 1997-03-11 Synaptic Pharmaceutical Corporation Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence

Also Published As

Publication number Publication date
EP0946174B1 (de) 2004-07-28
JP2001502336A (ja) 2001-02-20
CA2269031C (en) 2003-09-09
AU729675B2 (en) 2001-02-08
EP0946174A1 (de) 1999-10-06
WO1998016225A1 (en) 1998-04-23
IL129267A (en) 2003-10-31
AU4757297A (en) 1998-05-11
US5877198A (en) 1999-03-02
ATE271867T1 (de) 2004-08-15
DE69730045T2 (de) 2005-07-21
EP0946174A4 (de) 2002-10-23
CA2269031A1 (en) 1998-04-23
IL129267A0 (en) 2000-02-17

Similar Documents

Publication Publication Date Title
AR052921A1 (es) Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
BR0108977A (pt) Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina
ATE324119T1 (de) Verwendung von saccharid-konjugaten
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
ATE232396T1 (de) Oxydiertes thymosin beta 4
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
FI972308A (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
BR9808221A (pt) Método de tratamento de tumor.
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
BR0115882A (pt) Emprego de compostos de 1-fenil-3-dimetilaminopropano no tratamento da incontinência urinária
DE69730045D1 (de) Behandlung der harninkontinenz und zusammenstellung dafür
NO20032411L (no) Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
ATE341323T1 (de) Verwendung von darifenacin zur behandlung des harndrangs
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
TR200003084T2 (tr) Paroxetine askorbat
EA200200656A1 (ru) НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-е]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
AU5890499A (en) Use of composition in the treatment of schizophrenia
BG108033A (en) Use of 2-amino-1-(4-hydroxy-2-methane sulphonamidophenyl)ethanol for treating urinary incontinence.
TR199801800T2 (xx) Uykusuzluk tedavisi.
PT1304107E (pt) Utilizacao de derivados de oxazolidininas para o tratamento da psoriase

Legal Events

Date Code Title Description
8364 No opposition during term of opposition